GLPwatch
Papers (12034)
Page 188 of 201, ranked by citation count.
- Oral Health Considerations and Dental Management Guidelines for Semaglutide Medications.
- Semaglutide for obesity management: A narrative review of efficacy, safety, and future directions.
- Evaluation of the Efficacy of Semaglutide Dose Escalation in Reducing HbA1c Levels and Insulin Dose in Type 2 Diabetes Patients: Real-World Semaglutide Data from Türkiye, SEMA-TR Study.
- Residual gastric content after tirzepatide discontinuation: is one week enough?
- Weight loss as the optimal cardiometabolic management strategy for preventing and treating heart failure.
- Emulating the LEADER trial in China: a regulatory science case study on non-interventional research.
- GLP-1 Receptor Agonists and the Ocular Surface: A Narrative Review of Restoration, Remodeling, and Clinical Implications.
- Orforglipron (Foundayo) for adults with obesity.
- Is it time to reassess the role of myocardial metabolic modulation for the treatment of heart failure?
- BMI response to dapagliflozin with or without semaglutide across obesity classes: a real-world observational study conducted in Saudi Arabia.
- AI digital pathology as a key tool providing in-depth understanding of the progression and regression of MASH and fibrosis in male mouse models.
- [Type 2 diabetes treatment and cardiovascular risk: what can we learn from trials?]
- Assessing the risk of diabetic retinopathy progression with GLP-1 receptor agonists: a systematic review and meta-analysis.
- Tirzepatide for fertility-sparing treatment in obese/overweight patients with endometrial cancer and atypical hyperplasia: a phase II single-arm clinical trial protocol.
- Blamed but not at fault: anti-obesity medication adverse effects misidentified as perioperative complications - a comprehensive review and medicolegal warning for anesthesiologists.
- Weight Management With Semaglutide and Tirzepatide in U.S. Adults: Projected Impact on Obesity Prevalence and Heart Failure Risk.
- In brief: Higher-dose semaglutide (Ozempic) for type 2 diabetes.
- A Rare Case of Tirzepatide-Associated Immune Thrombocytopenia.
- Use of Tirzepatide in Adults with Type 2 Diabetes Mellitus: Scientific Evidence and Practical Aspects.
- Liraglutide enhances bone regeneration in a critical-size calvarial defect model in male rats: A comparative study with autogenous grafts, allografts, and xenografts.
- Diabetic ketoacidosis induced by liraglutide overdose for weight loss in a type 2 diabetes patient: A case report.
- A second case of liraglutide-type localised amyloidosis.
- Tirzepatide and the risk of atherosclerotic cardiovascular events: population based cohort study.
- The Paradox and Future of GLP-1/GIP Combination Therapies: Efficacy and Mechanisms.
- Concurrent initiation of tirzepatide and biologics improves patient-reported outcomes in obese psoriatic arthritis: a propensity score-matched study.
- Esophageal Motility Patterns Are Not Impacted By Glucagon-Like Peptide-1 Receptor Agonist Use.
- Roux-en-Y Gastric Bypass Compared to Glucagon-Like Peptide-1 Receptor Agonists is Associated with Lower Out-of-Pocket Costs in Insured Patients with Type 2 Diabetes and Obesity: A Matched Analysis Over Two Years.
- Tirzepatide Synergizes with Leptin on Weight Loss and Restoring Metabolic Homeostasis in Diet-induced Obesity Model.
- Efficacy and Safety of Retatrutide in the Treatment of Diabetes and/or Obesity Comorbid with Chronic Kidney disease: a Systematic Review and Meta-Analysis.
- Incretin-Based Therapies in Sports: Pharmacological Mechanisms, Performance-Enhancing Potential, and Anti-Doping Implications-A Narrative Review.
- Semaglutide and GLP-1 Agonists: Forensic and Medicolegal Implications.
- Response by Kosiborod et al to Letter Regarding Article, "Effects of Semaglutide on Symptoms, Function, and Quality of Life in Patients With Heart Failure With Preserved Ejection Fraction and Obesity: A Prespecified Analysis of the STEP-HFpEF Trial".
- Diabetes medications improve cardiovascular outcomes: the paradigm shifts.
- Once-Weekly Subcutaneous Semaglutide 2.4 mg Injection is Cost-Effective for Weight Management in Spain.
- Glucagon-like peptide-1 receptor agonist, semaglutide, attenuates intravenous self-administration of fentanyl in female rats.
- Production of a Dulaglutide Analogue by Apoptosis-Resistant Chinese Hamster Ovary Cells in a 3-Week Fed-Batch Process.
- Exendin-4 averts all-trans-retinal-driven damage to photoreceptors and the retina via the GLP-1R/PKA/CREB1 signaling axis.
- Experimental colonization with H. hepaticus, S. aureus and R. pneumotropicus does not influence the metabolic response to high-fat diet or incretin-analogues in wildtype SOPF mice.
- DNA-based delivery of incretin receptor agonists using MYO Technology leads to durable weight loss in a diet-induced obesity model.
- Insulin and Incretin Receptor Agonists Reciprocally Alter Their Blood-Brain Barrier Permeabilities.
- Glucagon-like peptide-1 receptor agonists and hair loss: A systematic review and meta-analysis.
- [Prescribing semaglutide for overweight: is it allowed?]
- Responses to GLP-1RA in White and Black Adults With Obesity: Insights From Generalized Additive Mixed Models of EHR Data.
- The Effect of Liraglutide on the Hypolipidemic, Anti-Inflammatory, and Antioxidant Properties of Atorvastatin Mediated via the Nrf2/HO-1 Signaling Pathway: In Vivo and In Silico Validation.
- AgRP neurons are required for the weight-lowering effects of GLP-1 receptor agonists in female mice.
- The Therapeutic Potential of Glucagon-Like Peptide-1 Receptor Agonists in Psoriasis and Hidradenitis Suppurativa.
- Glucagon-like peptide-1 receptor agonists after recent burn injury are associated with lower rates of infection, mortality, and opioid prescriptions.
- Liraglutide Effectiveness: Is There a Real-Word Clinical Benefit?
- Comparative Effects of Individual Glucagon-Like Peptide-1 Receptor Agonist-Based Medications on Direct Measurement of Body Composition Among Adults With Overweight or Obesity With or Without Type 2 Diabetes: A Systematic Review and Network Meta-Analysis of Randomised Controlled Trials.
- Effectiveness and Safety of Antidiabetic Medications in Hidradenitis Suppurativa: A Systematic Review.
- Significant elevation of serum CA19-9 and CA242 levels induced by dulaglutide.
- Efficacy and safety of novel antidiabetic drugs in patients with type 2 diabetes and chronic kidney disease: a network meta-analysis.
- Cardiovascular Outcomes and Safety of GLP-1 Receptor Agonists in Elderly Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.
- Will Tirzepatide Become a Game-Changer Anti-Obesity Drug?
- Comment on: Semaglutide and cardiovascular outcomes in obesity without diabetes.
- Association between tirzepatide use and risk of mortality, hospitalization, and suicidal behavior in patients with schizophrenia spectrum disorders: A one-year retrospective cohort study of 3618 patients.
- Tirzepatide Versus Intensified Conventional Care After 2 Years of Treatment in Early Type 2 Diabetes : A Randomized Clinical Trial.
- Improving sensitivity and drug tolerance of assays for neutralizing anti-drug antibodies to semaglutide and native GLP-1.
- Preventive effect of liraglutide on postoperative delirium in elderly patients undergoing cardiac surgery: protocol for a single-centre, randomised, double-blind, placebo-controlled trial.
- Tirzepatide Attenuates Wire Injury-Induced Arterial Remodeling in Non-Diabetic and Diabetic Mice: Comparison with Semaglutide.